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Abstract: Migraine is a neurobiological headache disorder that affects around 16% of adults in the
United States. Medical treatment of mild to moderate migraines include non-prescription non-
steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination
analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that
have not responded to analgesics can be treated with triptans, which are drugs specific for migraine
treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation
training. Medications for the prevention of migraines have also been developed since they are more
affective in offsetting the symptoms. Ubrogepant’s high specificity and selectivity for calcitonin
gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the
treatment of migraines with or without aura due to their decreased selectivity. The most frequently
reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found
that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo.
Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease.
In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to
hold promise for the acute treatment of migraines with or without aura in adults.
Keywords: ubrogepant; migraines; migraine treatment; abortive treatment; CGRP inhibitors
1. Introduction
Migraine is a neurobiological headache disorder that affects around 16% of adults in
the United States [1–3]. It is a recurring and disabling condition that can cause a reduction
in the quality of life including the ability to work or participate in social activities [1,4].
Migraine is caused by increased excitability of the central nervous system and is made
up of four phases: the premonitory, aura, headache, and postdrome [1,5–7]. Sensory
sensitivity is the greatest indicator of an individual in the premonitory phase which
precedes a headache [5]. The aura phase may also precede a headache, but it only presents
in around 30% of patients experiencing migraine [1,2,5]. An aura is caused by reactive
vasodilation to cerebral vasoconstriction along with cortical blood flow reduction [1,8]. It
Neurol. Int. 2021, 13, 32–45. https://doi.org/10.3390/neurolint13010004 https://www.mdpi.com/journal/neurolint
Neurol. Int. 2021, 13 33
can present with visual, hemisensory, and language abnormalities with visual being the
most common [2,5]. The headache phase is triggered by activation of the trigeminovascular
pathway which results in throbbing pain [5,6]. After the throbbing pain subsides, the
patient may experience fatigue, cognitive difficulties, or mood change, which are features
of the postdrome phase [5–7].
Patients experiencing migraine may be at a higher risk for certain psychiatric condi-
tions. For instance, patients suffering migraine with aura are three times more likely to
suffer from bipolar disorder compared to the general population [9–12]. Additionally, mi-
graineurs are at a higher risk for sleep disorders and are 2.5 times more likely to suffer from
depression [9,13–15]. Since stress can be a trigger for a migraine, abuse and post-traumatic
stress disorder show higher prevalence among migraineurs [9,16]. Therefore, migraine can
play a significant role in a patient’s mental health status.
Migraines can also be classified as chronic in nature or can happen whenever a
specific trigger is induced acutely. It can also be subdivided further into another type called
vestibular migraine. About 2% of the general population experiences chronic migraines [17].
In order to diagnose a patient with this condition, he/she must suffer from at least 15
days of headaches for at least three consecutive months [17]. Some symptoms of chronic
migraine include hypersensitivity to visual, auditory, and olfactory stimuli as well as
nausea and vomiting [17,18]. Vestibular migraine is the most common cause of episodic
vertigo [19,20]. Damage to the central vestibular and ocular motor systems may also be
seen in patients with vestibular migraine [20]. Treatment is still adapting for these types of
migraines as targets for them are different.
The newest class of medication approved to treat migraine in adults is known as
calcitonin gene-related peptide (CGRP) antagonists [3]. Among these are ubrogepant
and rimegepant, which inhibit CGRP at locations in the migraine pathway in order to
block vasodilation and neurogenic inflammation [3,21]. Ubrogepant is prescribed to adult
patients for acute migraine therapy with or without aura for acute, abortive treatment.
However, it is not indicated as a preventative treatment [3,21,22].
2. Migraines
Migraines are a type of headache disorder that can be quite disabling [23]. These
episodes can last for several hours or even days, and are impactful on a patient’s life. Many
mechanisms have been suggested to explain the pathophysiology of this fairly common
disorder. There are two major forms of migraines—with and without aura, with the latter
being headaches with additional neurological symptoms [23]. Many risk factors have been
associated with chronicity of migraines, most dealing with failure to effectively treat acute
migraines [24].
2.1. Epidemiology
Around the world, approximately 1–2% of people are afflicted with chronic mi-
graines [25]. Migraines affect 12% of the United States population, with some research
studies stating as high a prevalence of 16% [1,2]. Prevalence of migraines in the United
States varies by race. The highest prevalence being found among Caucasians while Asian
Americans have been found to have the lowest prevalence of migraines [25]. In about 3%
of patients, irregular episodes of migraines progress to chronic migraines. Females are
more likely to be affected by chronic migraines than males [24]. Some families have even
shown an autosomal dominant inheritance pattern of vestibular migraines [26–28].
2.2. Pathophysiology
While the exact mechanism of migraine pathophysiology is not completely understood,
research utilizing functional imaging suggests it involves both structural and functional
alterations in the brain [18]. One of the major areas is in the connecting circuits between the
thalamus and the cortex, and this can be identified during and after migraine episodes [5].
Such changes have also been identified in the various phases of chronic migraine episodes.
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The premonitory phase shows electrophysiological changes. It has been suggested that
these changes can manifest into processing of sensory information [5]. Structural and
functional changes have also been identified in the brainstem [18].
Altered connections in various regions of the brain have also been identified as
a potential source of migraines. These regions include the cortex, the thalamus, the
hypothalamus, the brainstem, the amygdala, and the cerebellum [5]. Increased excitability
has also been found in certain cortices involved in top-down processing [18]. This effect on
top-down processing is associated with increased levels of oxidative stress and increased
processing of nociceptive sensations. Therefore, these individuals are more sensitive to
sensations that lead to migraine episodes [24].
Migraines can be related to molecular changes. For example, CGRP is secreted by
trigeminal afferent nerves when the dura mater becomes inflamed. This release of CGRP
propagates pain signals during a migraine episode. In fact, CGRP can serve as a biomarker
in patients with chronic migraines [18]. Another molecule involved in the chronicity of
migraines is 5-hydroxytryptamine (5-HT), which is involved in the modulation of pain and
sleep pathways. Overuse of migraine medication and recurrent headaches can increase
5-HT, which results in serotonin receptor upregulation. This upregulation further enhances
repeated episodes of headaches, eventually leading to chronic migraines [18]. Pituitary
adenylate cyclase activating polypeptide (PACAP), also serves as a molecular influence on
the pathophysiology. Frequent headaches lead to a decrease in PACAP and increase in its
receptors which this is thought to serve a role in progression of migraines [18].
Drastic changes in the homeostasis of ions have been associated with visual aura.
Frequent changes from depolarization to hyperpolarization leads to an imbalance of ions
across cortical neurons, and large amounts of energy are needed to restore the balance. The
increased blood flow associated with this increased demand for energy has been identified
as a possible mechanism of visual aura [29].
2.3. Risk Factors
Various risk factors of migraines have been identified. Women are at greater risk of
having both chronic and more severe migraines than men [25]. The onset of migraines in
women is roughly before or near puberty and lasts well into postmenopausal stages [30].
Those with chronic migraines are more likely of lower socioeconomic status [31]. Another
risk factor is the overuse of acute migraine medication. With repetitive overuse of these
medications, the frequency of migraine episodes increases [24]. The risk of having chronic
migraines can also be doubled if acute migraines are treated ineffectively. Inadequately
treating migraines can also cause sensitization due to longer periods of experiencing
headaches [24]. Mood disorders have been associated with increased risk of chronic
migraines [18]. Comorbidities of chronic migraines includes diseases associated with the
respiratory, cardiovascular, and psychiatric disease. Specifically, chronic migraines are
twice as likely to be associated with recurrent bronchitis, ulcers, depression, and other pain
disorders [31].
2.4. Presentation
Patients experiencing migraines usually present with a combination of severe headaches
and vestibular symptoms [27]. Migraines without aura present with recurrent, unilateral
headaches that last between four hours and seventy-two hours. These headaches typically
worsen with activity, and patients may describe the pain as throbbing with moderate to
severe intensity [23]. For migraine with aura to be diagnosed, a patient would report
at least two episodes that involve one or more aura symptoms, which including some
unilateral visual, sensory, or other neurological symptoms, with visual aura being the
most common [23]. These episodes also include gradual increase in the aura symptoms,
development of unilateral aura symptoms, the duration of aura symptoms of under sixty
minutes, or having any aura symptoms with a headache [23,29].
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3. Current Treatment of Migraines
Migraine treatment consists of pharmacological, non-pharmacological, and neurostim-
ulation treatment [32]. Non-pharmacological treatment can be further broken down into
behavioral intervention. Pharmacological treatment will be discussed first. Treatments are
broken down into preventive and abortive in Table 1.
Table 1. Current Treatments in Migraines.







Beta Blockers (i.e., propranolol, metroprolol and timolol)
TCAs (i.e., mitriptyline)
Venlafaxine
Neurostimulation: nVNS, TMS, ONS, SMS therapies
Anti-CGRP monoclonal antibodies
non-steroidal anti-inflammatory drugs
Triptans (i.e., eletriptan, sumatriptan, frovatriptan and
naratriptan)
IV dihydroergotamine
CGRP antagonists (i.e., ubrogepant)
3.1. Pharmacological Treatments
First-line pharmacological treatment for migraines are used for mild to moderate mi-
graines when used alone, which include nonprescription non-steroidal anti-inflammatory
drugs (NSAIDs) such as aspirin, acetaminophen products, and caffeine-containing combi-
nation analgesics [32–34]. These analgesics are first-line therapies because they are low-cost,
effective, and practical since they are available over-the-counter [34]. Goldstein et al. found
that a combination of acetaminophen/aspirin/caffeine treatment in cases of more severe
migraines was more effective than 400 mg of ibuprofen [34]. Additionally, moderate to
severe migraines and those that are mild to moderate but have not responded to analgesics
can be treated with triptans, which are drugs specific for migraine treatment [34]. Triptans
are a family of drugs that function by binding to serotonergic receptors [34]. There are seven
different triptans currently used for treatment and they differ solely in their pharmacoki-
netics [34]. Triptans are 5-HT1B/1D receptor agonists with some affinity for the 5-HT1F [35].
Menstrual and hormone related migraines are a type of migraine that can be treated with
triptans [36]. Perimenstrual eletriptan is a recommended drug for menstrual migraines
which has been shown to cause a 46% decrease in headache activity [37]. Additionally,
frovatriptan and naratriptan, which are long acting triptans, can be used to decrease the
severity and frequency of menstrual migraines when used as short-term prevention [34].
Ditans are another class of medications, one of which that has been studied in lasmidi-
tan. Ditans are specific 5-HT1F agonist [35]. Two phase III trials, SAMURAI and SPARTAN,
looked at the use of lasmiditan in patients using concomitant migraine preventive med-
ications. Among those in the study, 17.5% were using preventative migraine treatment.
All doses of lasmiditan in these studies resulted in significantly more patients being pain
free at the two-hour mark [38]. The GLADIATOR study examined the long-term safety
and efficacy of Lasmiditan. This study found that at 100 mg and 200 mg was shown to
be generally well tolerated and efficacious for acute migraine treatment over a 1-year
period [39].
In emergency departments, NSAIDs and intravenous (IV) antiemetics are an effective
treatment that can be used with or without IV dihydroergotamine [34]. These drugs
work in reducing immediate pain but are not necessarily used for treating long-term
chronic migraines [32]. Opiates are not recommended for treatment of migraines due to
dependency [32]. The discussed treatments are good for acute abortive therapy. The next
sections look at possible preventive therapy of migraines.
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3.2. Behavioral Interventions
A study by Goldstein et al. found that nonprescription medications were first used
by more than fifty percent of patients in an attempt to treat their migraines before they
visited a physician due to unsuccessful treatment [40]. Cognitive behavioral therapy (CBT)
and relaxation training are nonpharmacological treatments associated with the prevention
of migraines as well as an improvement of symptoms [32]. These treatments are recom-
mended to be used alongside pharmacological treatment for chronic migraines [41,42].
Stress management is the traditional focus of CBT, while behavioral interventions, mindful-
ness, and meditation are directed towards treatment for comorbidities [41,42]. Relaxation
techniques aim to lower arousal of the sympathetic system as well as lower muscle tone to
promote relaxation of the body [41]. The focus of mindfulness therapies is to concentrate
on sensations of the body [32]. Additionally, biofeedback is a self-regulatory behavioral
intervention for migraine treatment with the purpose of helping patients acquire voluntary
control of certain physiologic functions [43]. For biofeedback therapy, a healthcare profes-
sional monitors patients carefully as their physiologic functions are detected via surface
sensors in real time, the results can be interpreted, and explain the process to the patient as
they work [41,43]. For the best management of migraines, adoption of behavioral therapies
alongside pharmacological treatment aids in treatment of symptoms as the avoidance of
their onset [41].
3.3. Neurostimulation
Neurostimulation modalities have recently provided advantageous treatment oppor-
tunities for migraines as they are not limited by side effects the way pharmacological
treatments are [32]. Non-invasive vagal nerve stimulation (nVNS), transcranial magnetic
stimulation (TMS), occipital nerve stimulation (ONS), and supraorbital transcutaneous
stimulation (SMS) therapies [32]. A handheld device is used to deliver nVNS, which
inhibits vagal afferent fibers, while having no effect on vagal efferents that could result
in bronchospasm and bradycardia [44]. A study by Silberstein et al. showed that some
patients who received nVNS treatment had a reducation in migraine days by more than
50% [45]. ONS functions through peripheral and central mechanisms to reduce pain as-
sociated with migraines by lowering activation of certain brain regions [32]. TMS works
by using a magnetic field to deliver a current to brain tissue which can cause functional
activation or functional deactivation of areas of the brain [32]. This treatment was found to
have favorable outcomes for patients who received treatment for migraines with aura [32].
Additionally, SMS, which is similar to ONS, is currently used for migraine prophylaxis
throughout Europe as well as in the United States [32]. A study by Magis et al. found that
patients who received SMS experienced a significant reduction in their number of headache
days as compared to the control group [46].
3.4. Preventative Treatments
Prevention is a major focus in migraine treatment because it can be more effective in
offsetting symptoms [32]. Some examples of effective classes of drugs in prevention are beta
blockers, tricyclic antidepressants, anticonvulsants and botulinum derivatives [32,33,47].
Topiramate, an anticonvulsant, has a method of action involves minimizing excitatory
effects as well as enhancing inhibitory effects, both of which work on neurotransmis-
sion [47]. The underlying anti-migraine mechanisms of topiramate’s activity potentially
include carbonic anhydrase isozymes inhibition, neurotransmitter release modulation, and
cell membrane ion channel regulation [47]. OnabotulinumtoxinA functions in prevent-
ing inflammatory neuropeptide release from trigeminal sensory neurons that have been
stimulated [47]. These two preventative treatments have been reported to help decrease
headache frequency, intensity of headaches, and number of doses required for symptomatic
treatment [32]. Additionally, Cho, Song, & Chu found that botulinum toxin A (BT-A) can
be effective in prevention of chronic migraines [32]. In patients receiving BT-A, occurrence
of side effects and failure of treatment was lower than topiramate [32]. In regard to the
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prevention of episodic migraine, propranolol is regarded as the first-choice drug [33,48].
Also listed as other first line medications for the prevention of migraine include other beta
blockers like metroprolol and timolol as well as divalproex [48]. Second line medications
are amitriptyline, venlafaxine, atenolol, and nadolol as there is some evidence that they
could be effective for prevention [48].
Anti-CGRP receptor monoclonal antibodies have been approved for the prevention
of migraine by the FDA as well [21]. These monoclonal antibodies are thought to block
the GCRP receptor and thereby downregulating the amount of glutamate which is re-
leased. These treatments are marketed under the names erenumab, galcanezumab, and
fremanezumab [21]. A study that looked at the efficacy of erenumab showed that patients
experienced fewer number of monthly migraine days than placebo [49]. The same findings
were observed with galcanezumab and fremanezumab [50,51]. The draw back on these
treatments is that they are self-administered injectables which can hinder the use in some
patients. Common side effects noted were redness and swelling at the injection site as well
as flu-like systems.
4. Urbrogepant
Urbrogepant is the first drug approved in the United States for the acute treatment
of migraine with or without aura [22,52,53]. However, it is not indicated for use as a
preventative treatment for migraines [22,54]. Ubrogepant is a highly selective, CGRP
antagonist which blocks the vasodilatory action of CGRP and CGRP’s involvement in
nociceptive transmission and modulation [22,52]. This medication can be equally as
effective in treating migraine-associated symptoms which include nausea, photophobia,
and sound sensitivity [54]. Ubrogepant shows a favorable safety profile, making it a
promising treatment [55].
4.1. Usage
Ubrogepant is typically taken orally with a recommended dose of either 50 or 100 mg [52,53].
After at least two hours, a second dose may be taken, but there is a maximum dose of
200 mg per day [52,53]. The elimination half-life is approximately 5–7 h, and it is excreted
mostly through fecal matter [53].
4.2. Cautions
If given in the presence of drugs that act as Cytochrome P450 3A4 (CYP3A4) inhibitors
or inducers, ubrogepant concentration must be monitored, as those drugs will increase
or decrease the amount of ubrogepant exposure, respectively [22,46]. Potent inhibitors
of CYP3A4 include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole,
ritonavir, verapamil, goldenseal and grapefruit. Inducers of CYP3A4 include phenobarbital,
phenytoin, rifampicin, St. John’s Wort and glucocorticoids.
Furthermore, the use of inhibitors for breast cancer resistance protein (BCRP) and
P-glycoprotein (P-gp) may increase exposure to ubrogepant, so patients on any medica-
tions which might alter levels should be monitored to assess needed dosage changes [53].
BCRP inhibitors include anti-HIV protease inhibitors nelfinavir and ritonavir, the di-
etary flavonoids chrysin and biochanin A and P-gp inhibitors include amiodarone, clar-
ithromycin, propafenone, and quinidine. Ubrogepant administration should be reduced to
a 50 mg dose in patients with severe renal impairment or avoided altogether in patients
with end stage renal disease as renal impairment will increase the patient’s exposure to the
drug [53]. This medication should also be avoided in pregnant patients related to its ability
to cause fetal harm [53].
5. Pharmacological Considerations
The sensation of migraine pain is thought to come from the activation of trigeminal
ganglia in the nervous system [56,57]. These ganglia have afferent fibers that project to
the spinal cord, synapse on various pain-sensing structures, and send signals of pain to
Neurol. Int. 2021, 13 38
auditory, visual, and motor cortices [56,57]. CGRP, which is abundant in these ganglia, is
released from nerve terminals. It is also secreted within the trigeminal ganglia to perpetuate
sensitization [56,58]. The sensitization is amplified by the interaction of CGRP with satellite
glial cells and nearby neurons [58]. Trigeminal nerves potentiate the spread of inflammatory
and neoplastic diseases, so the increased sensitivity of trigeminal nerves plays a role in the
painful feeling experienced during migraine [55,58].
Mechanism of Action
Ubrogepant has a high selectivity for CGRP receptors [59]. The exact sites for binding
of CGRP in relation to migraine are still unknown [60]. By decreasing the amount of
CGRP receptor binding, ubrogepant reduces the level of CGRP secreted into the trigeminal
ganglia [56,58]. Thus, ubrogepant indirectly decreases the sensitivity of trigeminal nerves
and reduces the amount of pain experienced [55,58]. Due to its ability to reduce pain in an
effective way, this drug works well as an acute treatment of migraines [56].
Ubrogepant is part of a class of molecules called gepants [57]. At clinically effective
exposures of ubrogepant, the drug does not cross the blood brain barrier [59]. Ubrogepant
also has a fairly short half-life, good tolerability, and high potency, and it does not affect
liver function. These properties make it a drug with a favorable safety profile [53,55,61,62].
6. Pharmacodynamics and Pharmacokinetics
Current treatments available to patients with migraines are limited by the non-specific
nature of these treatments. Some of these therapies are not viable options for individuals
with certain cardiovascular risk factors [63]. Ubrogepant is a possible treatment option for
patients with chronic migraine, as it is more selective, specifically for CGRP receptors. It is
safer for migraine patients with potential cardiovascular diseases as it does not prolong the
QT interval [64]. Subtherapeutic and supratherapeutic doses (100–400 mg) had no effect on
the QTc interval [64].
6.1. Pharmacodynamics
Ubrogepant has been shown to display antagonist activity of CGRP receptors with
high selectivity when compared to similar medications in the same calcitonin receptor
drug class [52,65]. Upon binding, ubrogepant blocks CGRP action to inhibit adeno-
sine monophosphate to alpha-CGRP stimulated cyclic adenosine monophosphate re-
sponses [59]. Due to low saturation of CGRP receptors in the central nervous system,
ubrogepant is known not to cross the blood brain barrier. While this does not explain
the exact site of action of ubrogepant, this does confirm that it acts on non-central CGRP
receptors, such as those in the trigeminal ganglia. Ubrogepant also shows some binding
affinity for amylin receptors in trigeminal ganglia [59].
6.2. Pharmacokinetics
Ubrogepant is rapidly absorbed after oral administration and reaches its peak plasma
concentration in roughly one and half hours [64,65]. Absorption of ubrogepant is affected
by consumption of food, delaying the time to reach peak plasma concentration by two
hours [64]. Metabolism of ubrogepant occurs primarily via CYP3A4 enzymes in the liver.
The main metabolites produced are M15 and M20 glucuronide conjugates, which circulate
in plasma [66]. The half-life of ubrogepant was found to be approximately 4 h following a
100 mg dose [65]. The main route of elimination is the biliary-fecal route while the minor
route of elimination is renal [64].
7. Clinical Studies
7.1. Phase I Studies
A randomized, placebo-controlled, multicenter, double-blind trial was conducted over
8 weeks with an initial 4-week screening period and a follow up period for safety, also
lasting 4-weeks [67]. The trial took place at 6 different centers across the United States
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starting in November 2017 and lasting until May 2018 [67]. Patients were randomized to
receive two placebo tablets or to receive 100 mg dose of ubrogepant as 2 pills of 50 mg [67].
The treatment was administered to patients two times a week at the trial centers [67].
Patients’ blood samples were analyzed post-dose at either 0.5 h, 1 h, or 2 h [67]. Safety
and tolerability were the primary outcomes measured [67]. The trial monitored treatment-
emergent adverse events (TEAEs) which were defined as presenting after the first dose
but also as adverse events (AEs) that previously presented but increased in severity after
the first dose [67]. Hepatic safety was closely monitored, and serum chemistry values
were taken at the two initial screening visits as well as on multiple days throughout the
trial [67]. The TEAEs of most interest were elevated alanine aminotransferase (ALT) or
aspartate aminotransferase (AST) levels and any suicidal behavior or ideation [67]. A total
of 518 participants were involved in the trial. A total of 26 participants from the placebo
and 26 of the participants from the ubrogepant group left the trial before completion,
leaving 468 of the original 516 participants to finish the double-blinded treatment period
lasting 8 weeks [67]. Ubrogepant and the placebo demonstrated similar overall incidence
of TEAEs: ubrogepant (44%) vs. placebo (45%) [67]. For TEAEs, 89% of participants in both
the placebo and ubrogepant groups experienced mild TEAEs while 11% of the placebo
group and 8% of the ubrogepant ground experienced TEAEs of moderate severity [67].
The TEAEs reported the most frequently were oropharyngeal pain, nasopharyngitis and
headache [67]. There were no participant deaths reported throughout the trial [67]. A
participant in the ubrogepant group also experienced serious AEs associated with a car
accident such as arthralgia, musculoskeletal pain, back pain, abdominal pain, and neck
pain [67]. Of the patients who left the trial, three members of the placebo group left the
trial due to dehydration, vomiting, influenza, pain in extremities, or tooth infection [67].
However, no patient in the ubrogepant group left due to AEs [67]. No patients reported
TEAEs related to suicidal behaviors or ideation, as measure on the Columbia-Suicide
Severity Rating Scale [67]. With regards to hepatic safety, only 3 members of the placebo
group and 2 members of the ubrogepant group presented with increased ALT levels and
4 members of the placebo group and no members of the ubrogepant group presented with
increased AST levels [67]. The trial identified no concerns with regards to safety associated
with ubrogepant at high-frequency doses [67]. This trial demonstrated that ubrogepant
at intermittent doses was not associated with elevation in levels of ALT or AST when
compared to the placebo, it was not associated with the development of any liver injury
deemed clinically significant [67].
7.2. Phase II Studies
A randomized computer-generated schedule was prepared in which participants were
designated to a group in a double-blinded manner by a statistician [68]. There was a total
of 834 participants randomized where 138 were assigned to 1 milligram of ubrogepant.
139 were assigned to 10 mg, 139 to 25 mg, 139 to 50 mg, 140 to 100 mg, and 139 to the
placebo [68]. The trial took place in the United States at 55 study centers starting in July 2012
lasting until December 2012 [68]. The most frequent post-dose AEs were nausea, dizziness,
fatigue, somnolence and dry-mouth, which presented within 48 h [68]. Within 14 days, the
most frequent AEs were the same as those presenting within 48 h [68]. The placebo and
ubrogepant groups had an incidence of AEs comparable to that associated with triptans,
with neither group exhibiting any instances of asthenia, dysesthesia, hypesthesia, or chest
or throat tightness [68]. There were no deaths or serious AEs within 14 days following the
dose and no patients left the trial due to AEs [68]. Only two serious AEs were observed,
both within the 50 mg group which were myoclonus occurring 15 days following treatment
and hypertension [68]. The trial found that at higher doses, ubrogepant was beneficial for
sustaining freedom from pain but also noted that further trials needed to be conducted for
more definitive conclusions [68]. Ubrogepant demonstrated a statistically significant rate
of success for freedom from pain within two hours that was higher than that of the placebo
(25.5% vs. 8.9%, p = 0.003) throughout the dose range [68]. Additionally, both the 25 mg
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and 50 mg dose of ubrogepant demonstrated a pain-free two-hour rate than the placebo
demonstrated (21% vs. 8.9%, p = 0.020 and 21.4% vs. 8.9%, p = 0.023 respectively) [68]. The
100 mg dose of ubrogepant showed a higher response rate to headaches compared to the
placebo but the difference was not found to be statistically significant (58.8% vs. 44.6%,
p = 0.061) [68]. Only the 25 mg, 50 mg, and 100 mg doses of ubrogepant demonstrated
significant superiority over the placebo [68]. The effects of ubrogepant were comparable to
those seen with telcagepant and triptans [68].
An additional trial was conducted to determine the safety, side effects, and efficacy
of ubrogepant. This trial was double-blinded, randomized, and placebo-controlled with
parallel groups [69]. Participants received either placebo, a 50 mg dose of ubrogepant,
or a 100 mg dose of ubrogepant after being randomized into groups based on prior use
of preventative migraine medication and prior response to triptans [69]. For the trial,
participants reported their pain as either no pain, mild pain, moderate pain, or severe
pain [69]. Additionally, they reported if various non-headache symptoms were absent or
present as different times: prior to initial dose; at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 14 and 48 h post
dose, at the time of the second dose if they chose to do a second dose, and at two hours
after the second dose [69]. Participants also stated the migraine symptom that bothered
each of them most and reported its presence or absence at 2 h following each dose [69].
A primary efficacy analysis was conducted to assess the percentage of the participants
who reported satisfaction with the treatment as well as the percentage who reported they
were able to function normally [69]. The trial consisted of 1672 participants who were
randomly assigned to 1 of 3 groups: 559 to placebo, 556 to 50 mg, and 557 to 100 mg [69].
The percentage of participants with freedom from pain 2 h following the initial dose was
11.8 of the placebo group, 19.2 of the 50 mg ubrogepant group (p = 0.002), and 21.2 of
the 100 mg group (p < 0.001) [69]. Absence of the migraine associated symptom deemed
most bothersome was reported in 27.8% of the placebo group, 38.6% of the 50 mg group
(p = 0.002), and 37.7% of the 100 mg group (p = 0.003) [69]. Additionally, 336 participants of
the 871 (38.6%) in the two ubrogepant groups choose to receive a second dose. Of those who
took the second dose, 20.0% received ubrogepant [69]. The percentage of participants who
experienced pain relief at the 2 h mark was 49.1% in the placebo group, 60.7% of the 50 mg
ubrogepant group (p = 0.002), and 61.4% of the 100 mg (p = 0.002) [69]. At the 2 h mark,
29.8% of the placebo group reported no disability and were able to function as normal,
40.6% of the 50 mg group reported no disability and ability to function as normal, and
42.9% of the 100 mg group reported no disability and ability to function as normal [69]. AEs
that presented or worsened within 48 h following the initial dose were reported in 12.9% of
the participants, and 26.3% of the participants reported AEs within 30 days following any
dose [69]. For this trial, the percentage of participants in the 50 mg dose or the 100 mg dose
of ubrogepant were free from pain and the absence of other migraine-associated symptoms
was higher among than those who received the placebo [69].
7.3. Phase III Trials
A randomized, multicenter, trial was conducted where patients were randomized to
either placebo, 25 mg, or 50 mg of ubrogepant in a 1:1:1 ratio [70]. Randomization was
based on past response to triptan treatment, and preventative migraine medication [70].
For the trial, participants took 1 tablet of their assigned medication as soon as possible
within 4 h of noticing their symptoms [70]. To qualify for the trial, patients had to meet
the following conditions: exhibit phonophobia or nausea, be able to self-administered
medicine within the 4-h window of symptom onset, have migraine headaches falling into
either moderate or severe category, have no usage of medicine that is prohibited (e.g.,
Ergot derivative, opioid, NSAIDs, antiemetic agents, analgesics, proton pump inhibitors,
or triptans), exhibit symptoms of a new migraine, and have had a migraine that was
not previously resolving [70]. At two hours after the initial dose, both the absence of
migraine-associated symptom considered most bothersome and pain were evaluated [70].
Freedom from pain was considered to be a reduction in headache severity from baseline of
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moderate to severe pain to no pain [70]. Participants completed the Functional Disability
Scale before dosing as well as at 1, 2, 4, and 8 h post original dose [70]. Patients responses
ranged from 0 which was ability to function at normal capacity to 3 which was considered
to be impaired in serious manner, cannot perform at their normal level, and may require
bed rest [70]. For the 50 mg group, patients reported freedom from pain at the 2-h mark
was significantly greater compared to the placebo (21.8% vs. 14.3%, p = 0.01) and the
25 mg group was also found to be significantly greater compared to the placebo (20.7% vs.
14.3%, p = 0.03) [70]. For patients reporting absence of the migraine-associated symptom
considered most bothersome at the 2 h mark, the percentage was significantly greater
for the 50 mg dose (38.9% vs. 27.4%, p = 0.01) compared to the placebo but was not
significantly greater for the 25 mg dose (34.1% vs. 27.4%, p = 0.07) [70]. All clinical studies
are summarized below in Table 2.
Table 2. Clinical Efficacy and Safety—Ubrogepant.
Author (Year) Groups Studied and Intervention Results and Findings Conclusions
Goadsby, P.J., et al.,
(2019)
Healthy males or females between the ages
of 18 and 50 years Participants were
required to have normal ALT and AST levels
and were excluded if they had any of the
following: sitting systolic blood pressure
≥140 or ≤90 mm Hg or diastolic blood
pressure ≥90 or ≤50 mm Hg, history of
clinically significant reaction or
hypersensitivity to CGRP.
For TEAEs, 89% of participants in both the
placebo and ubrogepant groups experienced
mild TEAEs while 11% of the placebo group
and 8% of the ubrogepant ground
experienced TEAEs of moderate severity.
The TEAEs reported the most frequently
were oropharyngeal pain, nasopharyngitis
and headache.
The trial identified no
concerns in regard to safety
associated with ubrogepant
at high-frequency doses.
Voss, T., et al.,
(2016)
Participants ranged from 18–65 years of with
a ≥1-year history of migraines who
experienced between two and 8 moderate or
severe migraine attacks every month for at
least two months prior to trial screening.
Ubrogepant demonstrated a statistically
significant rate of success for freedom from
pain within two hours that was higher than
that of the placebo (25.5% vs. 8.9%,
p = 0.003). Additionally, 50 mg dose of
ubrogepant demonstrated a nominally
significantly (p value < 0.05 unadjusted)
higher pain-free two-hour rate than the
placebo demonstrated (21% vs. 8.9%,
p = 0.020). The 100 mg dose of ubrogepant
showed a higher response rate to headaches
compared to the placebo but the difference
was not found to be statistically significant
(58.8% vs. 44.6%, p = 0.061).
Demonstrated a positive
response trend, measured
as the proportion of
participants achieving
freedom from pain after 2 h.
Dodick, D.W., et al.,
(2019)
Participants were between the ages of 18 and
75 years old with at least ≥1-year of history
of migraine and had onset of migraines
before the age of 50. Participants had to have
a history of migraines lasting between 4 to
72 h in length and migraines separated by at
least 48 h pain-free. Participants needed to
have a history of at least 2 to 8 migraines per
month that were rated as moderate or severe
with onset before 3 months of the start of
the trial.
The number of participants with
pan-freedom 2 h following the initial dose
was 11.8% of the placebo group, 19.2% of the
50 mg ubrogepant group (p = 0.002), and
21.2% of the 100 mg ubrogepant group
(p < 0.001).
The percentage of
participants in the 50 mg
dose or the 100 mg dose of
ubrogepant had




Lipton, R.B., et al.,
(2019)
Participants were between the ages of 18 and
75 years old with a history of migraine for at
least 1 year and experienced 2 to 8 migraine
attacks rated moderate to severe presenting
each month for 3 months before the
screening for the trial. Participants were
required to have migraine onset before the
age of 50 with 48 h of freedom from pain
between migraines.
For the 50 mg dose of ubrogepant, patients
reported freedom from pain at the 2-h mark
was significantly greater compared to the
placebo (21.8% vs. 14.3%, p = 0.01). The
25 mg dose was also found to be
significantly greater compared to placebo
(20.7% vs. 14.3%, p = 0.03).
Ubrogepant at doses of
50 mg and 25 mg was
found to produce greater
rates of freedom from pain
after 2 h compared to the
placebo [70].
8. Conclusions
Affecting over 16% of the entire United States population and approximately 1–2% of
the population around the world, migraine is a condition that impairs the daily activities
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of many individuals [2,25]. Therefore, it is important to find a treatment that can reduce
its painful symptoms in order to help patients return to their normal everyday lives.
Migraines can be treated in variety of different ways. Some patients may prefer the
pharmacological route while others may prefer the behavioral one. For avoidance of
medication, cognitive behavioral therapy, relaxation therapy, or nerve stimulation may
be ideal routes for treatment. On the other hand, if medication is preferred, there are a
few types that may be considered and some of them may be more effective than others.
NSAIDS, triptans, and some analgesics are known for the treatment of migraine, while
topiramate, propranolol, amitriptyline, divalproex, verapamil and OnabotulinumtoxinA
are examples of drugs used for preventative treatment [32,33,47]. Triptans and ditans are
similar as they both agonize a 5-HT receptor, however, ditans such as lasmiditan are specific
5-HTF1 agonists. Both triptans and ditans need to be taken within two hours of the start of a
migraine. Triptans are mostly nonspecific in terms of their receptor actions. Ubrogepant, by
contrast, is a specific CGPR antagonist. In addition, the emerging medication ubrogepant,
which has been very recently approved for the acute treatment of migraine with or without
aura, has been shown to be an effective and safe therapeutic agent. As of this writing, ditans
are not approved for use in the European Union, however, gepants such as ubrogepant are
approved [52].
As a CGPR antagonist, ubrogepant works to block CGRP release at locations within
the migraine pathway [3,21]. This drug’s high specificity and selectivity for CGRP sets
it apart from certain other drugs, which previously limited the treatment of migraines
with or without aura due to their decreased selectivity [53,59]. There are a few important
cautions to ubrogepant which are to avoid taking it when pregnant or with end stage renal
disease [53]. However, overall, it has good tolerability and an overall favorable safety
profile [55]. In conclusion, it appears to hold promise for the acute treatment of migraines
with or without aura in adults.
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